SynthesisMedical science monitor : international medical journal of experimental and clinical research2015
Prognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis.
Synthesis in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Prognostic and Clinicopathological Significance of Survivin Expression in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Scientific reports · 2016Pooled it
- Prognostic value of inflammation-based scores in patients with osteosarcoma.Scientific reports · 2016Trial
- Construction and evaluation of a prognostic model based on the expression of the metabolism-related signatures in patients with osteosarcoma.BMC musculoskeletal disorders · 2025Article
- The prognostic significance of lung immune prognostic index in patients with osteosarcoma after chemotherapy.Frontiers in oncology · 2025Article
- Comparison of Selected Non-Coding RNAs and Gene Expression Profiles between Common Osteosarcoma Cell Lines.Cancers · 2022Article
- miRNA‑218 targets multiple oncogenes and is a therapeutic target for osteosarcoma.Oncology reports · 2022Article
- Prospero homeobox 1 promotes proliferation, migration, and invasion of osteosarcoma cells and its clinical significance.Bioengineered · 2022Article
- Prognostic significance of modified lung immune prognostic index in osteosarcoma patients.Frontiers in genetics · 2022Article
- Osteosarcoma immune prognostic index can indicate the nature of indeterminate pulmonary nodules and predict the metachronous metastasis in osteosarcoma patients.Frontiers in oncology · 2022Article
- Combination of ultrathin micro-patterned MXene and PEDOT: Poly(styrenesulfonate) enables organic electrochemical transistor for amperometric determination of survivin protein in children osteosarcoma.Mikrochimica acta · 2021Article
- Article
- Adenovirus-mediated small interfering RNA targeting ezrin induces apoptosis and inhibits metastasis of human osteosarcoma MG-63 cells.Bioscience reports · 2018Article
- Correlation of IGF1R expression with ABCG2 and CD44 expressions in human osteosarcoma.Genes & genomics · 2018Article
- Correlations Between Hector Battifora Mesothelial-1 (HBME-1) Expression and Clinical Pathological Characteristics and Prognosis of Osteosarcoma Patients.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma is the most common primary bone malignancy and has poor prognosis. Survivin has been identified as an independent prognostic factor for a majority of cancers. In the present study, we evaluated the effect of survivin expression on the clinical outcome of osteosarcoma patients. MATERIAL AND
methodsOnline electronic databases were searched for related articles published between 2000 and 2015. Odds ratio (OR) and risk ratio (RR) with their 95% confidence intervals (CI) were employed to calculate the significance.
resultsOverall, a total of 20 relevant studies were selected, including 1030 patients. No significant heterogeneity was observed among included studies (P>0.01, I2<50%). Survivin was expressed in 68.6% of all cases. Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02). It was associated with the grade of osteosarcoma (Enneking clinical stage, IIb-III vs. I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs. I+II: OR=2.04, 95% CI=1.16-3.61, P=0.01), metastasis, and soft tissue invasion of osteosarcoma (OR=6.25, 95% CI=3.74-10.45, P<0.00001; OR=6.15, 95% CI=3.74-10.11, P<0.00001). No relationship was found between survivin expression and sex, age, or tumor size in patients with osteosarcoma.
conclusionsOur results suggest that survivin can function as a new diagnostic biomarker for osteosarcoma and be used as a reference index to determine pathology classification of osteosarcoma, providing new targets for gene therapy of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.